Browse > Article

Antiviral Potential of the Silkworm Deoxynojirimycin against Hepatitis B Virus  

You, Jung-Eun (Department of Life Science, College of Natural Sciences, The University of Suwon)
Seong, Su-Il (Department of Life Science, College of Natural Sciences, The University of Suwon)
Kim, Young-Ho (Department of Life Science, College of Natural Sciences, The University of Suwon)
Publication Information
International Journal of Industrial Entomology and Biomaterials / v.7, no.2, 2003 , pp. 139-144 More about this Journal
Abstract
Over 350 million people worldwide are chronic carriers of hepatitis B virus (HBV). Chronic viral infections of the liver can progress to cirrhosis, which may ultimately lead to hepatic failure or the development of hepatocellular carcinoma. There are two antiviral drugs on the market approved for clinical management of chronic HBV infections; interferon-alpha and the nucleoside analog lamivudine. However, they showed adverse side-effects. In the rational drug design for such therapies we would like to utilize antiviral drugs that inhibit the HBV replication in the liver. Investigation of natural extracts of silkworm exhibiting antiviral potential was held in the functional HBV polymerase activity and the release of virion particle in the HepG2.2.15 cell lines. HBV-producing transgenic mouse fed with silkworm DNJ molecule was shown as an inhibitor of serum HBV particles. We could represent this DNJ molecule as an antiviral potential complementing conventional therapies after preclinical tests against WHBV-infected animal model, woodchuck.
Keywords
Silkworm; 1-Deoxynojirimycin (1-DNJ); Priming reaction; HBV; HepG2.2.15; Transgenic mouse;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Fischer, P. B., G. B. Karlsson, R. A. Dwek and F. M. Platt (1996) N-butyldeoxynojirimycin-mediated inhibition ofHIV virus entry correlates with impaired gp120 shedding and gp41 exposure. J. Virol. 70, 7] 53-7160
2 Mehta, A., S. Carrouee, B. Conyers, R. Jordan, T. Butters, R.Dwek and T. M. Block (2001) Inhibition of HBV DNA repli-cation by imino sugars without the inhibition of the DNA polymerase- therapeutic implications. Hepatology 33, 1488-1495   DOI   ScienceOn
3 WHO. Hepatitis B. Fact Sheet WH0/204, November 1998
4 Blumberg, B. S. (1998) Hepatitis B virus: search for plant-derived antiviral; in Medical plants-their role in healh and biodiversity. Tomlinson T. R. and D. Akerele (eds.), PP. 7, University of Pennsylvania Press, Philadelphia
5 Purcell, R. H. (1990) The discovery ofthe hepatitis virus. Gas-troenteroloey 104, 955-963
6 Lu, X., A. Mehta, M. Dadmarz, R. Dwek, B. Blumberg and T. Block (1997) Aberrant trafficking of hepatitis B virus glyco-proteins in cells in which N-glycan processing is inhibited. Proc. Natl. Acad. Sci. USA 94, 2380-2385   DOI   ScienceOn
7 Sells, M. A., M. L. Chen and G. Acs (1987) Production of HBV virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA 84,1005-1009   DOI   ScienceOn
8 Lanford, R. E., Y. H. Kim, H. Lee, L. Notvall and B. Beames (1999) Mapping ofthe HBV reverse transcriptase TP and RT domains by transcomplementation for nucleotide priming and protein-protein interaction. J. Virol. 73, 1885-1893
9 Seeff, L. B., K. L. Lindsay, B. R. Bacon, T. F. Kresina and J. H. Hoofnagle (2001) Complementary and altemative medicine in chronic liver disease. Hepatology 34, 595-603   DOI   ScienceOn
10 Werr, M. and R. Prange (1998) Role for calnexin and N-linked glycosylation in the assembly and secretion of HBV virus middle envelope protein particles. J. Vtrol. 72, 778-782
11 Park, S. G. and G. Jung (2001) Human Hepatitis B Vims polymerase interacts with the molecular chaperonin Hsp60. J. Virol. 75, 6962-6968   DOI   ScienceOn
12 Korba, B. E. and J. L. Gerin (1992) Use of a standadized cell culture assay to assess activities of nucleoside analogs against HBV replication. Antiviral Res. 19, 55-70   DOI   ScienceOn
13 Zoulim, F. and C. Seeger (1994) Reverse transchption in hepa titis B virus is primed by a tyrosine residue of the poly-merase. J. Virol. 68, 6-13
14 Zitzmann, N., A. S. Mehta, S. Carrouee, T. D. Butters, F. M. Platt, J. McCauley, B. S. Blumberg, R. A. Dwek and T. M Block (1999) Imino sugars inhibit the formation and secre-tion of BVDV vims, a pestivims model of HCv: Implications for the development of broad spectrum anti-hepatitis vims agents. Proc. Natl. Acad. Sci. USA 96, 11878-11882   DOI   ScienceOn
15 Saunier, B., R. D. Kilker, J. S. Tkacz, A. Quaroni and A. Hers-covics (1982) Inhibition of N-linked complex oligosaccha-ride formation by l-DNJ, an inhibitor of processing glucosidases. J. Biol. Chem. 257, 14155-14161
16 Chen, R. W., H. Piparinen, M. Seppanen, P. Koskela, S. Sama and M. Lappalainen ( 2001) Real-time PCR for detection andquantitation of hepatitis B virus DNA. J. Med. Virol. 65, 250-256   DOI   ScienceOn
17 Hu, J. and C. Seeger (1996) Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 93, 1060-1064   DOI   ScienceOn
18 Korba, B. E. and G. Milman (1991) A cell culture assay for compounds which inhibit HBV replication. Antiviral Res. 15, 217-228   DOI   ScienceOn
19 Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacte.nophage $7_4$. Nature 227, 680-685   DOI   PUBMED   ScienceOn
20 Mehta, A., X. Lu, T. M. Block, B. S. Blumberg and R. A. Dwek (1997) HBV envelop glycoproteins vary drastically in their sensitivity to glycan processing: Evidence that alter-ation of a single N-linked glycosylation site can regulate HBV secretion. Proc. Natl. Acad. Sci. USA 94, 1822-1827   DOI   ScienceOn
21 Wang, G. H. and C. Seeger (1992) the reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA syn-thesis. Cell 71, 663-670   DOI   ScienceOn
22 Zoulim, F, J. Saputelli and C. Seeger (1994) Woodchuck HBV virus X protein is required for viral infection in vivo. J. Virol.68, 2026-2030
23 Mehta, A., N. Zitzmann, P. Rudd, T. Block and R. Dwek (1998) Alpha-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Letter 430, 17-22   DOI   ScienceOn
24 Lanford, R. E., L. Notvall and B. Beames (1995) Nucleotide phming and reverse transcnptase activity of Hepatitis B Virus polymerase expressed in insect cells. J. Virol. 69, 4431-4439
25 Liaw, Y. F. (1997) Current trends in therapy for chronic viral hepatitis. J. Gastromterol. Hepatol. 12, S346-S353   DOI   ScienceOn
26 Liu, J. M., H. Lin and H. Mclntosh (2001) Genus Phyllanthus for chronic hepatitis B Virus infection: a systematic review. J. Viral Hepatitis 8, 358-366   DOI   ScienceOn